Positron emission tomography imaging and drug development

Yaoxue Xuebao

Volumn 36, Issue 6, 2001, Pages 470-474

  Tang, Gang Hua ^a  

^a FIRST MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Drug development; Positron emission tomography imaging

Indexed keywords

ANIMAL; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG SCREENING; DRUG TOXICITY; HUMAN; PHARMACOKINETICS;

ANIMALS; DRUG EVALUATION; DRUG TOXICITY; HUMAN; PHARMACOKINETICS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0041731839     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Jones T. New opportunities in molecular imaging using PET [J], Drug Inf J, 1997,31(3):991-995.
2. Campbell B, Comar D. Guest editor's note: positron emission tomography (PET): a revolutionary new aproach to drug discovery and development [J]. Drug Inf J, 1997,31(3):989-990.
3. Pike VW. The status of PET radiochemistry for drug development and evaluation [J]. Drug Inf J, 1997,31 (3):997-1013.
4. Waarde AV. Measuring receptor occupancy with PET [J]. Curr Pharm Des, 2000,6(16):1593-1610.
5. Farde L. The advantage of using positron emission tomography in drug research [J]. Trends Neurosci, 1996,19(6):211-214.
6. Delforge J. The in vivo quantification of the receptor site concentration using ligand-receptor interaction modeling [J]. Drug Inf J, 1997,31(3):1019-1027.
7. Price P. Using PET to evaluate chemotherapy [J]. J Nucl Med, 1997,38(1):14N-14N.
8. Schwaiger M, Kosa I. Cardiovascular positron emission tomography: a possible tool for assessment of new pharmaceuticals [J]. Drug Inf J , 1997,31(3):1029-1034.
9. Andree B, Halldin C, Thorberg S, et al. Use of PET and the radioligand [carbonyl-(11) C] WAY-100635 in psychotropic drug development [J]. Nucl Med Biol, 2000,27(5):515-521.
10. 2 receptor occupancy in antipsychotic drug-treated patients [J]. J Clin Psychopharmacol, 1998,18(4):305-310.
11. Fowler JS, Volkow ND, Wang GJ, et al. PET and drug research and development [J]. J Nucl Med, 1999, 40 (7):1154-1163.
12. Volkow ND, Wang GJ, Fowler JS, et al. Relationship between psychostimulant induced high and dopamine transporter occupancy [J]. Proc Natl Acad Sci USA, 1996,93(20):10388-10392.
13. Kim S, Wagner HN, Villemagne VL, et al. Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system [J]. J Nucl Med, 1997,38(11):1726-1731.
14. Herholz K. PET evaluation of drugs in Alzheimer's and Parkinson's diseases [J]. Drug Inf J, 1997,31(3): 1035-1044.
15. Coleman RE, Bednarczyk EM, Chilton H. Positron emission tomography: from production and distribution to drug research and clinical applications [J]. J Am Pharm Assoc, 2000,40(5 suppl 1):S66-S67.
16. Price P, Harte R, Wells P, et al. The potential of tracer kinetic studies in drug development programs: a new investigational area for cancer research [J]. Drug Inf J, 1997,31(3):1045-1049.
17. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18] FLT and positron emission tomography [J]. Nat Med, 1998,4(10):1334 -1336.
18. Gambhir SS, Barrio JR, Herschman HR, et al. Imaging gene expression: principles and assays [J]. J Nucl Cardiol, 1999,6(2):219-233.
19. Gambhir SS, Barrio JR, Herschman HR, et al. Assay for noninvasive imaging of reporter gene expression [J]. Nucl Med Biol, 1999,26(5):481-490.
20. Phelps ME. PET: The merging of biology and imaging into molecular imaging [J]. J Nucl Med, 2000,41(4): 661-681.
21. Hospers GAP, Calogero A, Waarde AV, et al. Monitoring of herpes simplex virus thymidine kinase enzyme activity using positron emission tomography [J]. Cancer Res, 2000,60(3):1488-1491.
22. 2 receptor as a reporter gene in living animals [J]. Gene Ther, 1999,6(6):785-791.
23. Tavitian B, Terrazzino S, Kuhnast B, et al. In vivo imaging of oligonucleotides with positron emission tomography [J]. Nat Med, 1998,4(3):467-471.
24. Hustinx R, Eck SL, Alavi A. Potential applications of PET imaging in developing novel cancer therapies [J]. J Nucl Med, 1999,40(8):995-1002.
25. Haberkorn U, Bellemann ME, Gerlach L, et al. Uncoupling of 2-fluoro-2-deoxyglucose transport and phosphorylation in rat hepatoma during gene therapy with HSV thymidine kinase [J]. Gene Ther, 1998,5(7):880 -887.
26. 18F] fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography [J]. Antimicrob Agents Chemother, 1996, 40(3):659-664.
27. Volkow ND, Wang GJ, Fowler JS, et al. Enhanced sensitivity to benzodiazepines in cocaine abusers: a PET study [J]. Am J Psychiatry, 1998,155(2):200-206.
28. 11C] d - threo- and 1-threo-methylphenidate in the human and baboon brain [J]. Psychopharmacology, 1997,131(1):71-78.
29. Kissel J, Port RE, Zaers J, et al. Noninvasive determination of the arterial input function of an anticancer drug from dynamic PET scans using the population approach [J]. Med Phys, 1999,26(4):609-615.
30. Offord SJ, Wong DF, Nyberg S. The role of positron emission tomography in the drug development of M100907, a putative antipsychotic with a novel mechanism of action [J]. J Clin Pharmacol, 1999, Suppl:17S-24S.
31. 18F] fluorouracil pharmacokinetics [J]. J Nucl Med, 2000, 41(10):1714-1724.
32. 18F] BMY-14802, a potential antipsychotic drug [J]. J Nucl Med, 1993,34(2):246 -254.
33. Kabalka GW, Smith GT, Kyke JP, et al. Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning [J]. J Nucl Med, 1997,38(11): 1762-1767.
34. Vaalburg W. Preclinical pharmacokinetic PET studies with radiolabeled potential new drugs in man [J]. Drug Inf J, 1997,31(3):1015-1018.